Recap: Sage Therapeutics Q2 Earnings

Shares of Sage Therapeutics SAGE were flat in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share increased 36.59% over the past year to ($2.08), which beat the estimate of ($2.66).

Revenue of $1,089,000 rose by 24.74% from the same period last year, which beat the estimate of $890,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Aug 10, 2020

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/kkevgsu3

Recent Stock Performance

52-week high: $174.73

Company's 52-week low was at $25.01

Price action over last quarter: Up 30.05%

Company Description

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-547, it is in Phase 3 clinical trials for super-refractory status epilepticus; and the SAGE-217 program which is in Phase 2 clinical trials for post-partum depression, essential tremor, Parkinson's disease and major depressive disorder. The company is also developing several other compounds for treatment that is in the early stage of development.